Dapivirine ring for women's HIV prevention receives WHO prequalification

IPM's dapivirine ring for women's HIV prevention receives WHO prequalification
IPM's dapivirine vaginal ring could help fill an important gap with a long-acting product that a woman controls and could use discreetly to reduce her HIV risk during vaginal sex. The ring slowly releases the antiretroviral (ARV) drug dapivirine over the course of a month to reduce a woman's HIV risk. Women insert the product and replace it every month. Credit: Andrew Loxley, courtesy of IPM

The nonprofit International Partnership for Microbicides (IPM) is pleased to announce the World Health Organization's (WHO) prequalification of the dapivirine ring, a monthly vaginal ring to reduce women's HIV risk.

This designation from the WHO confirms that the ring meets global standards for quality, safety and efficacy. The product's addition to the WHO's list of prequalified medicines will help guide national and global procurement decisions, pending country regulatory approvals for its use. The ring's prequalification follows a positive scientific opinion for the product in July 2020 from the European Medicines Agency (EMA) under Article 58.

"WHO prequalification brings the dapivirine ring an important step closer to being made available to women, who want and deserve new choices in HIV prevention," said Dr. Zeda F. Rosenberg, founder and chief executive officer of IPM, which developed the dapivirine ring and is the product's regulatory sponsor. "Our aim is to make the ring available first in sub-Saharan Africa, where women face persistently high HIV risk."

The WHO prequalification program facilitates access to quality-assured medicines that respond to urgent public health priorities. Many countries consider prequalification in their regulatory reviews.

Women bear a disproportionate burden of the global HIV/AIDS epidemic, with nearly 60% of new adult infections in sub-Saharan Africa occurring among women. The monthly dapivirine ring could help fill an important gap with a long-acting product that a woman controls and could use discreetly to reduce her HIV risk during vaginal sex. Women insert the product and replace it every month. Made of flexible silicone, the ring slowly releases the antiretroviral (ARV) drug dapivirine in the vagina, with minimal absorption elsewhere in the body.

Expanding 's options so that they can choose the method that best meets their individual needs—whether systemic or non-systemic, long-acting, daily or on-demand—is essential to controlling the HIV/AIDS epidemic.

IPM will initially seek approvals for the ring's use in eastern and southern Africa where the need is urgent. First regulatory submissions will begin this year through a collaborative procedure led by the WHO that accelerates country regulatory reviews for products that have received a positive opinion from the EMA or other stringent regulatory authority. IPM will also submit an application to the US Food and Drug Administration in 2020.


Explore further

European Medicines Agency adopts positive opinion on monthly vaginal ring to reduce HIV risk

Provided by International Partnership for Microbicides (IPM)
Citation: Dapivirine ring for women's HIV prevention receives WHO prequalification (2020, November 30) retrieved 18 January 2021 from https://medicalxpress.com/news/2020-11-dapivirine-women-hiv-prequalification.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments